SCHEMBL22359809

SCHEMBL22359809

Cc1ccccc1Cn1cc(Br)c2cc(C#N)ccc21

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPT P10636 1/20 0.45
TSHR P16473 5/20 0.41
LMNA P02545 3/20 0.41
GAA P10253 2/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
GALR3 O60755 1/20 0.41
RAB9A P51151 1/20 0.41
KDM4E B2RXH2 1/20 0.40
HTR6 P50406 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP19A1 P11511 2/20 0.38
TP53 P04637 1/20 0.38
KLKB1 P03952 1/20 0.38
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20837882 0.84 TP53 (0.44) ALDH1A1SMN1; SMN2MAPTTSHRLMNA
SCHEMBL22359606 0.82 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTTSHRLMNA
SCHEMBL28597800 0.82 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2MAPTTSHRLMNA
SCHEMBL20604669 0.82 MEN1 (0.57) ALDH1A1SMN1; SMN2MAPTTSHRLMNA
SCHEMBL20604616 0.81 LMNA (0.46) ALDH1A1SMN1; SMN2MAPTTSHRLMNA
SCHEMBL20604620 0.81 LMNA (0.46) ALDH1A1SMN1; SMN2MAPTTSHRLMNA
SCHEMBL20604679 0.80 LMNA (0.45) ALDH1A1SMN1; SMN2MAPTTSHRLMNA
SCHEMBL20604642 0.79 HTT (0.49) ALDH1A1SMN1; SMN2MAPTTSHRLMNA
SCHEMBL20604670 0.78 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2MAPTTSHRLMNA
SCHEMBL20604603 0.74 CYP19A1 (0.46) ALDH1A1SMN1; SMN2MAPTTSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423443-B1 CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS NOVARTIS AG (CH) 2020-08-19 EP disclosed